FAMILIAL CHYLOMICRONEMIA SYNDROME TREATMENT MARKET ANALYSIS

Familial Chylomicronemia Syndrome Treatment MarketSize and Trends

Non-renewal of Glybera and launch of Volanesorsen to govern the total Familial Chylomicronemia Syndrome treatment market growth

In September 2017, Akcea Therapeutics Inc., a subsidiary of Ionis Pharmaceutical Inc., announced the filing of New Drug Submission (NDS) to Health Canada for Volanesorsen with the focus to develop and commercialize drugs to treat severe cardio metabolic disease caused by lipid disorder. Volanesorsen is designed to decrease the production of ApoC-III protein production in liver, which plays a vital role in the regulation of plasma TG. The Health Canada granted priority review to the drug for the treatment of Familial Chylomicronemia Syndrome in Canada, which could help accelerate the access of this medicine to the people of Canada suffering from FCS and is expected to fuel the growth of Familial Chylomicronemia Syndrome treatment market in this region. Akcea Therapeutics achieved successful results in its phase 3 trails - APPROACH Study and is currently conducting the APPROACH Open Label Study to further evaluate its efficacy with extended administration of the drug in FCS patients.